Author Correction: Chronic Kidney Disease Impairs Bone Defect Healing in Rats (Scientific Reports, (2016), 6, 1, (23041), 10.1038/srep23041);Chronic kidney disease impairs bone defect healing in rats

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Liu, Weiqing ^a   Kang, Ning ^a   Seriwatanachai, Dutmanee ^b   Dong, Yuliang ^a   Zhou, Liyan ^a   Lin, Yunfeng ^a   Ye, Ling ^a   Liang, Xing ^a   Yuan, Quan ^a  

^a SICHUAN UNIVERSITY   (China)

^b MAHIDOL UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL; CHRONIC KIDNEY FAILURE; COMPLICATION; CYTOCHEMISTRY; DISEASE MODEL; FRACTURE; FRACTURE HEALING; MALE; MICRO-COMPUTED TOMOGRAPHY; PATHOPHYSIOLOGY; RAT; UREMIA;

ANIMALS; DISEASE MODELS, ANIMAL; FRACTURE HEALING; FRACTURES, BONE; HISTOCYTOCHEMISTRY; MALE; RATS; RENAL INSUFFICIENCY, CHRONIC; UREMIA; X-RAY MICROTOMOGRAPHY;

EID: 84960492582     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-020-65651-4     Document Type: Erratum

References (49)

1. Saran, R., Hedgeman, E., Huseini, M., Stack, A. & Shahinian, V. Surveillance of chronic kidney disease around the world: tracking and reining in a global problem. Adv Chronic Kidney Dis 17, 271-281, doi: 10.1053/j.ackd.2010.03.001 (2010).
2. Jha, V., et al. Chronic kidney disease: global dimension and perspectives. Lancet 382, 260-272, doi: 10.1016/S0140-6736(13)60687-X (2013).
3. Coresh, J., et al. Prevalence of chronic kidney disease in the United States. JAMA 298, 2038-2047, doi: 10.1001/jama.298.17.2038 (2007).
4. Zhang, L., et al. Prevalence of chronic kidney disease in China: a cross-sectional survey. Lancet 379, 815-822, doi: 10.1016/S0140-6736(12)60033-6 (2012).
5. Pelletier, S. & Chapurlat, R. Optimizing bone health in chronic kidney disease. Maturitas 65, 325-333, doi: 10.1016/j. maturitas.2009.12.021 (2010).
6. Moe, S., et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 69, 1945-1953, doi: 10.1038/sj.ki.5000414 (2006).
7. Miller, P. D. Chronic kidney disease and osteoporosis: evaluation and management. Bonekey Rep 3, 542, doi: 10.1038/bonekey.2014.37 (2014).
8. Atsumi, K., et al. Risk factors for vertebral fractures in renal osteodystrophy. Am J Kidney Dis 33, 287-293 (1999).
9. Alem, A. M., et al. Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int 58, 396-399, doi: 10.1046/j.1523-1755.2000.00178.x (2000).
10. Bucur, R. C., et al. Low bone mineral density and fractures in stages 3-5 CKD: an updated systematic review and meta-Analysis. Osteoporos Int 26, 449-458, doi: 10.1007/s00198-014-2813-3 (2015).
11. Schober, H. C., et al. Mineralized bone loss at different sites in dialysis patients: implications for prevention. J Am Soc Nephrol 9, 1225-1233 (1998).
12. Nickolas, T. L., et al. Bone mass and microarchitecture in CKD patients with fracture. J Am Soc Nephrol 21, 1371-1380, doi: 10.1681/ASN.2009121208 (2010).
13. Lee, M. M., et al. Characterization of mandibular bone in a mouse model of chronic kidney disease. J Periodontol 81, 300-309, doi: 10.1902/jop.2009.090379 (2010).
14. Dijakiewicz, M., et al. Is implanto-prosthodontic treatment available for haemodialysis patients ?. Nephrol Dial Transplant 22, 2722-2724, doi: 10.1093/ndt/gfm317 (2007).
15. Coresh, J., Astor, B. C., Greene, T., Eknoyan, G. & Levey, A. S. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 41, 1-12, doi: 10.1053/ajkd.2003.50007 (2003).
16. Gilbertson, D. T., et al. Projecting the number of patients with end-stage renal disease in the United States to the year 2015. J Am Soc Nephrol 16, 3736-3741, doi: 10.1681/ASN.2005010112 (2005).
17. Kimura, G. Predicted prevalence in Japan of chronic kidney disease (CKD). Clin Exp Nephrol 11, 188-189, doi: 10.1007/s10157-007-0474-7 (2007).
18. Artzi, Z., Tal, H. & Dayan, D. Porous bovine bone mineral in healing of human extraction sockets: 2. Histochemical observations at 9 months. J Periodontol 72, 152-159, doi: 10.1902/jop.2001.72.2.152 (2001).
19. Lee, D. Z., Chen, S. T. & Darby, I. B. Maxillary sinus floor elevation and grafting with deproteinized bovine bone mineral: a clinical and histomorphometric study. Clin Oral Implants Res 23, 918-924, doi: 10.1111/j.1600-0501.2011.02239.x (2012).
20. Piattelli, M., Favero, G. A., Scarano, A., Orsini, G. & Piattelli, A. Bone reactions to anorganic bovine bone (Bio-Oss) used in sinus augmentation procedures: a histologic long-term report of 20 cases in humans. Int J Oral Maxillofac Implants 14, 835-840 (1999).
21. Araujo, M. G., Liljenberg, B. & Lindhe, J. Dynamics of Bio-Oss Collagen incorporation in fresh extraction wounds: an experimental study in the dog. Clin Oral Implants Res 21, 55-64, doi: 10.1111/j.1600-0501.2009.01854.x (2010).
22. Zigdon, H., Lewinson, D., Bick, T. & Machtei, E. E. Vertical bone augmentation using different osteoconductive scaffolds combined with barrier domes in the rat calvarium. Clin Implant Dent Relat Res 16, 138-144, doi: 10.1111/j.1708-8208.2012.00452.x (2014).
23. Kato, E., Lemler, J., Sakurai, K. & Yamada, M. Biodegradation property of beta-tricalcium phosphate-collagen composite in accordance with bone formation: a comparative study with Bio-Oss Collagen(R) in a rat critical-size defect model. Clin Implant Dent Relat Res 16, 202-211, doi: 10.1111/j.1708-8208.2012.00467.x (2014).
24. Cai, Y. H. & Lu, C. S. [A clinical study of gelatamp colloidal silver gelatin sponge on preventing the complication of teeth extraction]. Hua Xi Kou Qiang Yi Xue Za Zhi 26, 519-521 (2008).
25. Wang, Y. Z., et al. [Use of "gelatamp" colloidal silver gelatin sponge to prevent dry socket after extracting mandibular impacted teeth]. Shanghai Kou Qiang Yi Xue 22, 108-110 (2013).
26. Zou, H., et al. Effect of chronic kidney disease on the healing of titanium implants. Bone 56, 410-415, doi: 10.1016/j.bone.2013.07.014 (2013).
27. Liu, W., et al. Vitamin D supplementation enhances the fixation of titanium implants in chronic kidney disease mice. PLoS One 9, e95689, doi: 10.1371/journal.pone.0095689 (2014).
28. Sherrard, D. J., et al. The spectrum of bone disease in end-stage renal failure-An evolving disorder. Kidney Int 43, 436-442 (1993).
29. Couttenye, M. M., et al. Low bone turnover in patients with renal failure. Kidney Int Suppl 73, S70-76 (1999).
30. Hiramatsu, R., et al. Osteomalacia and insufficiency fracture in a hemodialysis patient with autosomal dominant polycystic kidney disease. Intern Med 51, 3277-3280 (2012).
31. Spicer, P. P., et al. Evaluation of bone regeneration using the rat critical size calvarial defect. Nat Protoc 7, 1918-1929, doi: 10.1038/ nprot.2012.113 (2012).
32. He, Y. X., et al. Impaired bone healing pattern in mice with ovariectomy-induced osteoporosis: A drill-hole defect model. Bone 48, 1388-1400, doi: 10.1016/j.bone.2011.03.720 (2011).
33. Li, S., et al. A pivotal role of bone remodeling in granulocyte colony stimulating factor induced hematopoietic stem/progenitor cells mobilization. J Cell Physiol 228, 1002-1009, doi: 10.1002/jcp.24246 (2013).
34. Kramann, R., et al. Osteogenesis of heterotopically transplanted mesenchymal stromal cells in rat models of chronic kidney disease. J Bone Miner Res 28, 2523-2534, doi: 10.1002/jbmr.1994 (2013).
35. Gomes, P. S. & Fernandes, M. H. Rodent models in bone-related research: the relevance of calvarial defects in the assessment of bone regeneration strategies. Lab Anim 45, 14-24, doi: 10.1258/la.2010.010085 (2011).
36. Shyng, Y. C., Devlin, H. & Sloan, P. The effect of streptozotocin-induced experimental diabetes mellitus on calvarial defect healing and bone turnover in the rat. Int J Oral Maxillofac Surg 30, 70-74, doi: 10.1054/ijom.2000.0004 (2001).
37. Santana, R. B., et al. A role for advanced glycation end products in diminished bone healing in type 1 diabetes. Diabetes 52, 1502-1510 (2003).
38. Durao, S. F., et al. Bone regeneration in osteoporotic conditions: healing of subcritical-size calvarial defects in the ovariectomized rat. Int J Oral Maxillofac Implants 27, 1400-1408 (2012).
39. Moe, S. M., et al. A rat model of chronic kidney disease-mineral bone disorder. Kidney Int 75, 176-184, doi: 10.1038/ki.2008.456 (2009).
40. Schindeler, A., McDonald, M. M., Bokko, P. & Little, D. G. Bone remodeling during fracture repair: The cellular picture. Semin Cell Dev Biol 19, 459-466, doi: 10.1016/j.semcdb.2008.07.004 (2008).
41. Monfoulet, L., Rabier, B., Chassande, O. & Fricain, J. C. Drilled hole defects in mouse femur as models of intramembranous cortical and cancellous bone regeneration. Calcif Tissue Int 86, 72-81, doi: 10.1007/s00223-009-9314-y (2010).
42. Monfoulet, L., et al. Bone sialoprotein, but not osteopontin, deficiency impairs the mineralization of regenerating bone during cortical defect healing. Bone 46, 447-452, doi: 10.1016/j.bone.2009.09.007 (2010).
43. Campbell, T. M., Wong, W. T. & Mackie, E. J. Establishment of a model of cortical bone repair in mice. Calcif Tissue Int 73, 49-55 (2003).
44. Komatsu, D. E., et al. Longitudinal in vivo analysis of the region-specific efficacy of parathyroid hormone in a rat cortical defect model. Endocrinology 150, 1570-1579, doi: 10.1210/en.2008-0814 (2009).
45. Hock, J. M. & Gera, I. Effects of continuous and intermittent administration and inhibition of resorption on the anabolic response of bone to parathyroid hormone. J Bone Miner Res 7, 65-72, doi: 10.1002/jbmr.5650070110 (1992).
46. Riggs, B. L. & Melton, L. J. 3rd. The prevention and treatment of osteoporosis. N Engl J Med 327, 620-627, doi: 10.1056/NEJM199208273270908 (1992).
47. Ma, Y. L., et al. Catabolic effects of continuous human PTH (1-38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-Associated bone formation. Endocrinology 142, 4047-4054, doi: 10.1210/endo.142.9.8356 (2001).
48. Jilka, R. L. Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. Bone 40, 1434-1446, doi: 10.1016/j. bone.2007.03.017 (2007).
49. Hodsman, A. B., et al. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev 26, 688-703, doi: 10.1210/er.2004-0006 (2005).